Summary
Bristol-Myers Squibb Company (BMY) filed an 8-K on July 25, 2013, to report its financial results for the second quarter of 2013. The filing primarily serves as a notification that the company has issued a press release detailing these results and has also provided supplemental financial information on its website. Investors can find the detailed financial performance, operational outcomes, and any forward-looking statements within the referenced press release and supplemental data. The key takeaway for investors is that this 8-K acts as a gateway to BMY's most recent financial performance disclosures. While the 8-K itself does not contain the detailed figures, it directs stakeholders to the official documents where these important metrics, such as revenue, earnings per share, and divisional performance, are disclosed. Investors should refer to Exhibit 99.1 and Exhibit 99.2 for a comprehensive understanding of BMY's second-quarter 2013 financial condition and results of operations.
Key Highlights
- 1BMY filed an 8-K on July 25, 2013, to report second-quarter 2013 financial results.
- 2The filing's primary purpose is to announce the issuance of a press release containing the financial results.
- 3A press release (Exhibit 99.1) detailing the Q2 2013 financial performance is furnished.
- 4Supplemental financial information, not included in the press release, is also available on the company's website (Exhibit 99.2).
- 5Investors are directed to these exhibits for a complete understanding of the company's financial condition and results of operations for the period.